- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- April 2018
- 195 Pages
Global
From €14213EUR$14,995USD£11,874GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
Bazedoxifene is a selective estrogen receptor modulator (SERM) used to treat endocrine and metabolic disorders. It is used to treat postmenopausal osteoporosis, as well as to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. Bazedoxifene works by blocking the effects of estrogen in certain parts of the body, while also acting like estrogen in other parts of the body. This helps to reduce the risk of bone loss and breast cancer.
Bazedoxifene is available in both oral and injectable forms. It is typically taken once daily, with or without food. Common side effects include hot flashes, nausea, and headache. Bazedoxifene should not be used by pregnant or breastfeeding women, or those with a history of stroke or blood clots.
The bazedoxifene market is a growing segment of the endocrine and metabolic disorders drugs market. It is used to treat a variety of conditions, including postmenopausal osteoporosis and breast cancer. As the population ages, the demand for bazedoxifene is expected to increase.
Some companies in the bazedoxifene market include Pfizer, Merck, and Eli Lilly. Show Less Read more